Pharmaron completed the acquisition of Aesica Pharmaceuticals from Recipharm.

Pharmaron, a company that provides research and manufacturing service, completed the acquisition of Aesica Pharmaceuticals, a pharmaceutical contract development and manufacturing organisation, from Recipharm, a CDMO. Financial terms were not disclosed. “We are delighted to have the Cramlington Site join the Pharmaron Group. This acquisition complements and further enhances Pharmaron’s CMC capabilities in the United Kingdom and China. We are committed to expanding the Cramlington Site to meet growing demand. Together with our API manufacturing facility expansion in China, this transaction is another important step in realizing our vision of becoming a leading global provider of integrated small molecule drug R&D and manufacturing services," Boliang Lou, Pharmaron Chairman and CEO.